TABLE 1

Baseline (1999–2002), Max0–2.5 and follow-up (2012–2013) characteristics of the cohort (n=203)

BaselineMax0–2.5Follow-up
Age years46.0±13.746.7±13.758.2±13.6
Male85 (41.9)85 (41.9)85 (41.9)
BMI kg·m−227.1 (24.1–29.7)26.9 (23.9–29.6)28.1 (24.4–31.2)
Smoking status
 Never-smoker100 (49.3)96 (47.3)
 Ex-smoker67 (33.0)77 (37.9)
 Current smoker36 (17.7)30 (14.8)
Pack-years#11 (5–20)16 (7–30)
DL % pred96.9±18.993.4±17.7
DLVA % pred100.4±18.495.2±16.3
Daily use of ICS16 (8.0)188 (96.4)155 (76.4)
Pre-bronchodilator lung function
 FEV1 L2.85 (2.33–3.32)3.19 (2.60–3.87)2.64 (2.17–3.16)
 FEV1 % pred82.8 (71.0–92.2)91.0 (83.0–102.0)86.0 (76.0–96.0)
 FEV1/FVC0.75 (0.69–0.80)0.79 (0.73–0.83)0.73 (0.66–0.79)
 FVC L3.73 (3.18–4.44)4.07 (3.40–4.91)3.66 (3.12–4.38)
 FVC % pred90.3 (79.8–100.4)97.3 (87.8–105.9)96.0 (87.0–106.0)
Post-bronchodilator lung function
 FEV1 L3.02 (2.51–3.55)2.75 (2.27–3.31)
 FEV1 % pred88.0 (76.6–98.9)90.0 (80.0–98.0)
 FEV1/FVC0.79 (0.74–0.83)0.75 (0.69–0.80)
 FVC L3.85 (3.28–4.52)3.77 (3.16–4.43)
 FVC % pred94.0 (82.0–102.1)98.5 (88.0–107.3)
 FEV1/FVC <0.731 (16.3)54 (26.6)
Atopy68 (37.2)
  • Data are presented as mean±sd, n (%) or median (interquartile range). Max0–2.5: point of highest lung function (forced expiratory volume in 1 s (FEV1) % pred) during the first 2.5 years after baseline; BMI: body mass index; DL: diffusing capacity of the lung; VA: alveolar volume; ICS: inhaled corticosteroids; FVC: forced vital capacity. #: ex- and current smokers; : as defined by positive skin-prick test towards common aeroallergen.